-+ 0.00%
-+ 0.00%
-+ 0.00%

Iridex Announces Publication Of 2-Yr Clinical Study Demonstrating Favorable Outcomes With TLT Using MicroPulse Technology In Patients With Primary Glaucoma

Benzinga·10/12/2026 11:01:43
Listen to the news

Iridex Corporation (NASDAQ:IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the publication of a two-year clinical study demonstrating favorable outcomes with transscleral laser therapy (TLT) using MicroPulse® Technology (referred to as MicroPulse TLT) in patients with early, moderate, and advanced primary glaucoma.